熱門資訊> 正文
Revolution Pharmaceuticals因支持第三阶段计划的daraxonrasib数据而上涨
2025-09-11 05:16
- Revolution Medicines (NASDAQ:RVMD) said that new clinical results from several phase 1 clinical trials support moving daraxonrasib into a phase 3 program for first-line metastatic pancreatic ductal adenocarcinoma (PDAC).
- The company noted that the three-arm phase 3 trial would start in Q4.
- In one of the phase 1 trials, a long-term follow-up (median follow-up of 16.7 months) in second-line+ PDAC, participants were given daraxonrasib 300 mg daily. Results showed that median progression-free survival was 8.5 months and 8.1 months, respectively, based on a RAS G12X mutation (n=26) or any RAS mutation. For median overall survival the figures were 13.1 months and 15.6 months.
- Another phase 1 trial as first-line treatment with treatment-naïve RAS-mutant PDAC patients treated with daraxonrasib 300 mg daily showed an objective response rate of 47% and a disease control rate of 89% with a median follow-up of 9.3 months.
- The company noted that another phase 3 trial for daraxonrasib as a second-line PDAC treatment is on schedule to finish enrollment by the end of the year with data available in 2026.
- Revolution Medicines is up ~8% in after-hours trading Wednesday.
More on Revolution Medicines
- Revolution Medicines, Inc. 2025 Q2 - Results - Earnings Call Presentation
- Revolution Medicines, Inc. (RVMD) Q2 2025 Earnings Call Transcript
- Revolution Medicines: Positioning Itself To Capture One Of The Largest Cancer Targets In History
- Summit draws Neutral view on risk/reward setup as Piper initiates biotech cancer names
- Revolution Medicines outlines $1.03B–$1.09B net loss guidance for 2025 amid expanded global RAS portfolio strategy
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
